Literature DB >> 15856016

A mutation hotspot at the p14ARF splice site.

Mark Harland1, Claire F Taylor, Philip A Chambers, Kairen Kukalizch, Juliette A Randerson-Moor, Nelleke A Gruis, Femke A de Snoo, Jeanet A C ter Huurne, Alisa M Goldstein, Margaret A Tucker, D Timothy Bishop, Julia A Newton Bishop.   

Abstract

Germline mutations of CDKN2A that affect the p16INK4a transcript have been identified in numerous melanoma pedigrees worldwide. In the UK, over 50% of pedigrees with three or more cases of melanoma have been found to carry mutations of CDKN2A. Mutations that affect p14ARF exon 1beta exclusively are very rare. This has led to the suggestion that it is p16INK4a and not p14ARF that plays the critical role in melanoma predisposition. We report the identification of a cluster of five different germline mutations at the p14ARF exon 1beta splice donor site in melanoma pedigrees. All the five splice site variants showed evidence of being causal mutations. Three of the variants were demonstrated to result in aberrant splicing of the p14ARF mRNA, confirming their role in melanoma predisposition. No other point mutations were identified in the coding region of p14ARF. The p14ARF transcript of CDKN2A is clearly important in disease predisposition in a subset of melanoma pedigrees. Curiously, the only mutations so far reported to affect p14ARF exon 1beta exclusively have been knockout mutations. Further investigation into the spectrum of mutations observed in this gene may help clarify the exact role of p14ARF in melanoma predisposition.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15856016     DOI: 10.1038/sj.onc.1208678

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  17 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

2.  Absence of germline CDKN2A mutation in Sicilian patients with familial malignant melanoma: Could it be a population-specific genetic signature?

Authors:  Sara Di Lorenzo; Daniele Fanale; Bartolo Corradino; Valentina Caló; Gaetana Rinaldi; Viviana Bazan; Antonio Giordano; Adriana Cordova; Antonio Russo
Journal:  Cancer Biol Ther       Date:  2016       Impact factor: 4.742

3.  Aberrant Expression of p14ARF in Human Cancers: A New Biomarker?

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Tumor Microenviron       Date:  2019-02-04

4.  Chimeric negative regulation of p14ARF and TBX1 by a t(9;22) translocation associated with melanoma, deafness, and DNA repair deficiency.

Authors:  Xiaohui Tan; Sarah L Anzick; Sikandar G Khan; Takahiro Ueda; Gary Stone; John J Digiovanna; Deborah Tamura; Daniel Wattendorf; David Busch; Carmen C Brewer; Christopher Zalewski; John A Butman; Andrew J Griffith; Paul S Meltzer; Kenneth H Kraemer
Journal:  Hum Mutat       Date:  2013-06-03       Impact factor: 4.878

Review 5.  Genetic determinants of cutaneous melanoma predisposition.

Authors:  Durga Udayakumar; Bisundev Mahato; Michele Gabree; Hensin Tsao
Journal:  Semin Cutan Med Surg       Date:  2010-09

6.  A flexible multiplex bead-based assay for detecting germline CDKN2A and CDK4 variants in melanoma-prone kindreds.

Authors:  Julie M Lang; Michael Shennan; Jenny C-N Njauw; Su Luo; Julia N Bishop; Mark Harland; Nicholas K Hayward; Margaret A Tucker; Alisa M Goldstein; Maria T Landi; Susana Puig; Nelleke A Gruis; Wilma Bergman; Giovanna Bianchi-Scarra; Paola Ghiorzo; David Hogg; Hensin Tsao
Journal:  J Invest Dermatol       Date:  2010-11-18       Impact factor: 8.551

7.  Frequent p16-independent inactivation of p14ARF in human melanoma.

Authors:  Daniel E Freedberg; Sushila H Rigas; Julie Russak; Weiming Gai; Margarita Kaplow; Iman Osman; Faye Turner; Juliette A Randerson-Moor; Alan Houghton; Klaus Busam; D Timothy Bishop; Boris C Bastian; Julia A Newton-Bishop; David Polsky
Journal:  J Natl Cancer Inst       Date:  2008-05-27       Impact factor: 13.506

8.  A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL).

Authors:  Mark Harland; Alisa M Goldstein; Kairen Kukalizch; Claire Taylor; David Hogg; Susana Puig; Celia Badenas; Nelleke Gruis; Jeanet ter Huurne; Wilma Bergman; Nicholas K Hayward; Mitchell Stark; Hensin Tsao; Margaret A Tucker; Maria Teresa Landi; Giovanna Bianchi Scarra; Paola Ghiorzo; Peter A Kanetsky; David Elder; Graham J Mann; Elizabeth A Holland; D Timothy Bishop; Julia Newton Bishop
Journal:  Eur J Cancer       Date:  2008-04-03       Impact factor: 9.162

9.  Compensatory signals associated with the activation of human GC 5' splice sites.

Authors:  Jana Kralovicova; Gyulin Hwang; A Charlotta Asplund; Alexander Churbanov; C I Edvard Smith; Igor Vorechovsky
Journal:  Nucleic Acids Res       Date:  2011-05-23       Impact factor: 16.971

Review 10.  Mechanisms of TP53 Pathway Inactivation in Embryonic and Somatic Cells-Relevance for Understanding (Germ Cell) Tumorigenesis.

Authors:  Dennis M Timmerman; Tessa L Remmers; Sanne Hillenius; Leendert H J Looijenga
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.